Ovid Therapeutics OVID
2.40
(0.10)
(4.00%)
as of 25 Sep
- Market cap
- $487.3M
- P/E
- 0.0×
Follow OVID
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 0.00 | 1.81 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | 0.00 | 0.00 | 0.65 | 597.77 | 116.51 | 16.57 |
P/FCF ratio |
— | — | — | — | 0.00 | 1.83 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | (9.31) | (18.05) | (14.89) | (19.67) | (6.59) | (11.55) |
P/B ratio |
— | — | — | — | 3.09 | 1.21 | 1.03 | 2.67 | 0.97 | 0.92 |
Price to Tangible BV |
— | — | — | — | 3.12 | 1.21 | 1.03 | 2.68 | 0.97 | 0.92 |
EV/Sales |
— | — | — | — | 0.00 | 0.00 | 0.11 | 365.43 | 46.44 | 8.62 |
EV/EBITDA |
— | — | — | — | 0.00 | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | (1.22) | 0.24 | (0.43) | (3.13) | (0.47) | (1.63) |
EV/FCF |
— | — | — | — | (1.21) | 0.24 | (0.42) | (3.12) | (0.47) | (1.63) |
Quick Ratio |
13.91 | 14.47 | 4.76 | 7.39 | 3.27 | 12.69 | 18.45 | 9.22 | 5.04 | 8.40 |
Current Ratio |
14.04 | 14.71 | 5.01 | 7.58 | 3.39 | 12.87 | 18.79 | 9.55 | 5.32 | 8.97 |
Net Debt/EBITDA |
2.31 | 1.34 | 0.79 | 1.25 | 0.89 | (1.51) | 2.09 | 1.55 | 0.65 | 1.37 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.35% | 0.08% | 0.00% | 10.31% | 10.25% | 14.56% | 7.94% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.17 | 0.20 | 0.09 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 1.54 | 0.01 | 0.00 | 0.00 | 0.06 |
Operating CF/Net income |
0.79 | 0.49 | 0.88 | 0.85 | 0.64 | 0.99 | 1.02 | 0.87 | 2.12 | 2.20 |
Capex/Depreciation |
(3.35) | (0.59) | (2.48) | (0.96) | (1.27) | (0.80) | (1.03) | (0.24) | (0.26) | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (38.20%) | (97.66%) | (85.04%) | (111.11%) | (142.60%) | 107.30% | (34.72%) | (47.57%) | (33.88%) | (17.51%) | |
| (36.33%) | (90.97%) | (75.82%) | (94.11%) | (103.38%) | 88.61% | (30.97%) | (34.98%) | (22.38%) | (14.33%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (180.14%) | 0.00% | (135.38%) | (36.33%) |
Return on Tangible Assets |
(46.01%) | (78.44%) | (146.45%) | (87.19%) | (153.14%) | 68.12% | (43.15%) | (52.92%) | (57.65%) | (26.25%) |
Average Days of Receivables |
0.00 | — | 0.00 | 0.00 | 4.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 502.63% | 22.53% | 1,638.28% | 7,292.86% | 6,495.94% | 352.76% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 242.77% | 17.87% | 2,158.28% | 7,929.85% | 4,537.81% | 332.45% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 59.64% | 2.43% | 436.33% | 1,858.42% | 1,108.83% | 66.29% |
Graham Net Nets |
— | — | — | — | 0.32 | 0.81 | 0.79 | 0.23 | 0.49 | 0.45 |
Graham Number |
— | — | — | — | 0.00 | 10.30 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | (60.61%) | 55.14% | (39.69%) | (22.59%) | (40.86%) | (13.82%) |
Free Cash Flow Yield |
— | — | — | — | (38.49%) | 54.64% | (41.46%) | (19.57%) | (85.08%) | (32.02%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 3.09 | 0.02 | 0.01 | 0.01 | 0.10 |
Operating CF per Share |
(1.81) | (1.63) | (1.85) | (1.30) | (0.88) | 1.76 | (0.78) | (0.65) | (0.79) | (0.52) |
Capex per Share |
(0.02) | 0.00 | (0.01) | (0.01) | (0.01) | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.83) | (1.63) | (1.86) | (1.31) | (0.89) | 1.75 | (0.80) | (0.65) | (0.79) | (0.52) |
Cash per Share |
5.28 | 4.50 | 1.68 | 1.96 | 1.23 | 2.78 | 1.83 | 1.50 | 0.75 | 0.94 |
Shareholders Equity per Share |
5.01 | 4.31 | 1.58 | 1.79 | 0.75 | 2.66 | 1.88 | 1.24 | 0.96 | 1.77 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.01 | 4.31 | 1.58 | 1.79 | 0.75 | 2.66 | 1.88 | 1.24 | 0.96 | 1.77 |
Free Cash Flow |
(17.99) | (31.52) | (45.91) | (51.33) | (51.97) | 118.42 | (56.65) | (45.92) | (56.12) | (38.33) |
Working Capital |
48.68 | 82.57 | 35.42 | 69.28 | 52.78 | 175.68 | 124.39 | 98.13 | 45.42 | 66.08 |
Capital Expenditures |
(0.19) | (0.05) | (0.35) | (0.24) | (0.39) | (0.19) | (1.42) | (0.14) | (0.16) | — |
Net Current Asset Value |
48.68 | 82.57 | 35.42 | 68.99 | 42.55 | 175.68 | 108.39 | 53.37 | 32.00 | 54.09 |
EV/EBIT |
— | — | — | — | 0.00 | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.94 | 0.35 | 0.28 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | (642.26%) | 57.51% | (3,604.78%) | (13,351.79%) | (4,670.14%) | (240.13%) |
Price to Operating Income |
— | — | — | — | 0.00 | 1.74 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.30 | 1.55 | 2.03 | 3.73 | 2.26 | 0.98 | 1.20 | 0.74 | 1.42 | 1.08 |
Cash ROIC |
(17.63%) | (18.48%) | (56.82%) | (34.79%) | (44.69%) | 32.21% | (20.33%) | (22.34%) | (41.86%) | (18.18%) |
Accounts Receivable Turnover |
0.00 | — | 0.00 | 0.00 | 19.82 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | — | — | — |
Average Receivables |
0.30 | — | 0.30 | 0.87 | 0.64 | — | — | — | — | — |
Average Payables |
0.76 | 1.44 | 2.89 | 3.51 | 4.35 | 6.29 | 4.54 | 2.83 | 3.45 | 2.57 |
Average Assets |
61.70 | 71.24 | 68.55 | 64.25 | 78.38 | 135.24 | 174.91 | 149.65 | 118.10 | 121.55 |
Average Common Equity |
58.67 | 66.36 | 61.12 | 54.41 | 56.83 | 111.69 | 156.01 | 110.04 | 78.01 | 99.44 |
Columns are period end dates